# US 8,465,736 B2 · Glutadon

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,465,736 B2
- Document ID: US8465736B2
- Status: Granted
- Kind: B2
- Application number: 12/300,209
- Filed: 2007-05-10
- Published: 2009-07-02
- Granted: 2013-06-18
- Earliest claimed: 2006-05-10
- Assignees: New Medical Enzymes AG
- Applicants: Michael Bausch; Wetzler Rainer; Christian Muller
- Inventors: Michael Bausch; Wetzler Rainer; Christian Muller
- Web page: https://patentgrep.com/patent/US8465736B2

## CPC

- A61K 38/50: acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a pharmaceutical combination product for cancer therapy. The combination product comprises the two active ingredients glutaminase and 6-diazo-5-oxo-L-norleucine (DON). The invention further relates to the use of such a combination product for the treatment of cancers.

## Claims

### Claim 1

A combination product for cancer treatment, which combination product comprises the active ingredients
a) glutaminase and
b) 6-diazo-5-oxo-L-norleucine (DON),
where active ingredient a) is present in a dosage of from 40 I.U./m2 to 300 I.U./m2 based on a recipient; and
where active ingredient b) is present in a dosage of from 105 to 185 mg/m2 based on a recipient, where in the glutaminase is a glutaminase asparaginase from Pseudomonas 7A.

### Claim 2 (depends on 1)

The combination product as claimed in claim 1, characterized in that active ingredient a) is modified and/or provided with one or more protective substances.

### Claim 3 (depends on 1)

The combination product as claimed in claim 1, characterized in that active ingredient a) is present in a concentration of from 50 I.U./m2 to 200 I.U./m2 (international units per body surface area of recipient), based on a recipient, in the combination product.

### Claim 4 (depends on 1)

The combination product as claimed in claim 1, characterized in that active ingredient a) is intended for administration three times a week to once every four weeks.

### Claim 5 (depends on 1)

The combination product as claimed in claim 1, characterized in that active ingredient b) is intended for administration four times a week to once every two weeks.

### Claim 6 (depends on 1)

The combination product as claimed in claim 1, characterized in that active ingredients a) and b) are present in a conjoint administration unit.

### Claim 7 (depends on 6)

The combination product as claimed in claim 6, characterized in that active ingredients a) and b) are present in two separate administration units
A) comprising active ingredient a) and
B) comprising active ingredient b).

### Claim 8 (depends on 7)

The combination product as claimed in claim 7, characterized in that at least one administration unit is in injectable form.

### Claim 9 (depends on 7)

The combination product as claimed in claim 7, characterized in that at least one administration unit is in intravenous form.

### Claim 10 (depends on 7)

The combination product as claimed in claim 7, characterized in that at least one administration unit is in oral form.